Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AtaiBeckley Inc. - Common Stock (NQ:ATAI)

3.845 -0.025 (-0.65%)
Streaming Delayed Price Updated: 3:35 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AtaiBeckley Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
News headline image
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
From atai Life Sciences
Via GlobeNewswire
DOD to Invest $9.8m into Psychedelic Studies Targeting Active-Duty Soldiers
Via Investor Brand Network
News headline image
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Study Finds That Bad Psychedelic Trips Double Some Individuals’ Fatality Risk
Via Investor Brand Network
News headline image
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
From atai Life Sciences
Via GlobeNewswire
Veterans Turn to One Another for Help Using Psychedelics to Combat Mental Health Challenges
Via Investor Brand Network
News headline image
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months ↗
Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca. 
Via Stocktwits
News headline image
Trade Desk Posts Downbeat Revenue, Joins Aspen Aerogels, Fastly And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
atai Life Sciences Announces Pricing of Public Offering of Common Shares
From atai Life Sciences
Via GlobeNewswire
News headline image
Wondering what's happening in today's after-hours session? ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
atai Life Sciences Announces Proposed Public Offering of Common Shares
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
From atai Life Sciences
Via GlobeNewswire
News headline image
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS ↗
President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services. 
Via Investor's Business Daily
Topics Government
News headline image
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care? ↗
AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth ↗
Atai Life Sciences reports Q3 results, highlighting FDA clearance for DMT film, upcoming MDMA trials, and a strong cash position. 
Via Benzinga
News headline image
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
From atai Life Sciences
Via GlobeNewswire
News headline image
Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes ↗
Over 5 million Americans with depression could be eligible for psilocybin-assisted therapy if FDA-approved, signaling vast market potential. 
Via Benzinga
News headline image
Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies ↗
Companies are developing safer, targeted psychedelic therapies aimed at reducing risks and improving mental health treatment options. 
Via Benzinga
News headline image
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week ↗
The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come. 
Via Talk Markets
News headline image
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward? ↗
 
Via Benzinga
News headline image
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th ↗
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are... 
Via Talk Markets
News headline image
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August ↗
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a... 
Via Talk Markets
News headline image
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration ↗
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development. 
Via Benzinga
Topics Artificial Intelligence
News headline image
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From atai Life Sciences
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.